Previous Close | 9.08 |
1-Year Change | -8.93% |
6-Months Change | -29.12% |
3-Months Change | -27.53% |
Moving Avg (50d) | 11.2039 |
Moving Avg (200d) | 13.0583 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 191.2M |
Beta (3-Years) | 0.99 |
Revenue Growth (ttm) | -9.87% |
Net Profit Margin (ttm) | -163.86% |
Return On Assets (ttm) | -26.67% |
EPS (ttm) | -1283.88 |
PE Ratio (ttm) | -0.01 |
Dividend Yield | % |
Asset Description: | Enanta Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-11 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
9.262 | 9.534 | 9.716 | 9.988 | 10.442 | 10.896 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |